Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7159041 | 0.99 | ITGB3 (0.38) | ITGB3ITGA2BKAT6APPARDHTR2A | |
| SCHEMBL7135473 | 0.94 | ITGB3 (0.42) | ITGB3ITGA2BKAT6APPARDHTR2A | |
| Hydrochloric Acid SCHEMBL7160727 | 0.94 | ITGB3 (0.42) | ITGB3ITGA2BKAT6APPARDHTR2A | |
| SCHEMBL7123146 | 0.91 | PPARD (0.45) | KAT6APPARDF2HTR1AHTR7 | |
| SCHEMBL7130847 | 0.90 | KAT6A (0.38) | KAT6APPARDHTR2AHTR1AHTR7 | |
| SCHEMBL7129812 | 0.89 | KAT6A (0.37) | KAT6APPARDHTR2AHTR1AHTR7 | |
| SCHEMBL7131920 | 0.88 | KAT6A (0.45) | KAT6AHTR2A | |
| SCHEMBL7130350 | 0.88 | CA1 (0.40) | ITGB3ITGA2BKAT6APPARDHTR2A | |
| Hydrochloric Acid SCHEMBL7159037 | 0.87 | CA1 (0.40) | ITGB3ITGA2BKAT6APPARDHTR2A | |
| SCHEMBL7248289 | 0.86 | KDM4E (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | claimed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | ITGB3 3260/4885ITGA2B 2276/4885KAT6A 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.